Rigel Pharmaceuticals
RIGL
156 hedge funds and large institutions have $640M invested in Rigel Pharmaceuticals in 2026 Q2 according to their latest regulatory filings, with 26 funds opening new positions, 57 increasing their positions, 56 reducing their positions, and 27 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
62% more call options, than puts
Call options by funds: $4.11M | Put options by funds: $2.53M
48% more capital invested
Capital invested by funds: $433M → $640M (+$208M)
1.89% more ownership
Funds ownership: 86.65% → 88.53% (+1.9%)
2% more repeat investments, than reductions
Existing positions increased: 57 | Existing positions reduced: 56
4% less first-time investments, than exits
New positions opened: 26 | Existing positions closed: 27
2% less funds holding
Funds holding: 159 → 156 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$56.6M |
| 2 |
AC
Armistice Capital
New York
|
+$12.1M |
| 3 |
American Century Companies
Kansas City,
Missouri
|
+$6.08M |
| 4 |
NAMI
Nomura Asset Management International
Philadelphia,
Pennsylvania
|
+$6.01M |
| 5 |
BlackRock
New York
|
+$5.27M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$9.3M |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$7.12M |
| 3 |
Nuveen
Charlotte,
North Carolina
|
-$6.58M |
| 4 |
Goldman Sachs
New York
|
-$6.55M |
| 5 |
Two Sigma Investments
New York
|
-$6.11M |
RIGL Hedge Fund Activity: Q2 2026 in Review
156 of the 8,305 institutional investors tracked by Wall St. Rank reported a position in Rigel Pharmaceuticals (RIGL) for Q2 2026, worth a combined $640M — up 48% from $433M a quarter earlier.
Sellers outnumbered buyers: 27 funds closed out of RIGL and 26 opened new positions — a net loss of 1 holder — while 56 trimmed existing stakes and 57 added.
The largest buyer was Soleus Capital Management, adding an estimated $56.6M. The largest seller was Qube Research & Technologies (QRT), exiting entirely with an estimated $9.3M sold.
- 156 institutional investors held Rigel Pharmaceuticals (RIGL) as of Q2 2026, down from 159 in Q1 2026.
- Funds reported $640M of Rigel Pharmaceuticals stock for Q2 2026, up 48% quarter-over-quarter.
- 26 funds opened new Rigel Pharmaceuticals positions in Q2 2026 and 27 closed out, a net change of -1 holder.
- The largest Rigel Pharmaceuticals buyer in Q2 2026 was Soleus Capital Management, an estimated $56.6M added.
- The largest Rigel Pharmaceuticals seller in Q2 2026 was Qube Research & Technologies (QRT), an estimated $9.3M sold.
Based on aggregated 13F filings for Q2 2026.